Those who live with myasthenia gravis (MG) can feel trapped in a cycle of frustration—a cycle of limited therapeutic options and symptom flare-ups, a cycle of required rest and social isolation. MycarinGstudy is a clinical research study that will evaluate a potential new subcutaneous (under the skin) treatment called rozanolixizumab against placebo. A placebo looks similar to a study drug but contains no medicinally active ingredients. MycarinGstudy was designed with the MG community from several countries.
To be eligible* for MycarinGstudy, you must:
Be diagnosed with generalized MG (gMG)
Be 18 years or older
Have mild to severe MG symptoms involving more than just the eyes
*Other criteria will also apply
In this 18-week study, participants will receive 6 weekly subcutaneous infusions of the study drug over a 5-week period, as well as routine tests and monitoring up to week 6. In addition, throughout the study, participants in MycarinGstudy will have:
Study drugs will be given subcutaneously with short infusion times.
Study doctors and their teams will closely monitor your condition and wellbeing throughout the study. Participants enrolling in MycarinGstudy can remain on selected background medications. Please talk to the study doctor for more information.
We encourage honest and open communication between participants and the study team.
Why a clinical research study?
Clinical research studies can help to advance the understanding of a disease and are the primary way that researchers find out if potential new treatments are well tolerated and effective. New treatments cannot become widely available without these studies. MycarinGstudy is a Phase 3, randomized, double-blind, placebo-controlled study; let’s break down those terms:
- Phase 3: Clinical studies take place over four different phases to check that the potential new treatment is well tolerated and that it works in the anticipated way. A Phase 3 study is the last stage of research before a treatment may be approved.
- Placebo-controlled: In order to test how effective the study drug is, researchers will compare it to a placebo. A placebo looks similar to the study drug but contains no medicinally active ingredients. Some study participants will receive the study drug, while others will receive a placebo.
- Randomized: In order to maintain the accuracy of the study, participants will receive the study drug or a placebo by random selection—similar to drawing straws.
- Double-blind: To ensure all data is collected in a fair way without judgment or preconceptions, neither participants nor the study team will know who is receiving the study drug and who is receiving a placebo.
People decide to participate in clinical studies for a variety of reasons. Some wish to contribute to medical research and to potentially help others with the same condition. Others may wish to try a different research approach. Clinical studies are completely voluntary, and you can withdraw at any time without providing a reason.
UCB, a global biopharmaceutical company based in Belgium, is developing rozanolixizumab and is sponsoring the MycarinGstudy.
We have listened and will keep listening to the evolving needs of participants throughout MycarinGstudy. UCB is engaging with organizations that support people with MG to better understand their needs.
MycarinGstudy is currently enrolling
We are looking to partner with the MG community and their doctors to help evaluate a potential new subcutaneous treatment option.
questions about MycarinGstudy?
If you’ve got questions about the study, we’ve got answers.